Our postulation was further supported by recent literature stating Adalimumab is a monoclonal antibody targeting the inflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha) blocker that has been associated with increased risk of serious infections like tuberculosis by suppressing the host immune system [18]. This evidence concerns the gene TNF and tuberculosis.